| | PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalitiesEdited by Robert Barouki Received 19 October 2009; received in revised form 7 December 2009; accepted 11 December 2009. published online 17 December 2009. Abstract Proprotein convertase subtilisin/kexin type 9 (PCSK9), a liver-secreted plasma enzyme, restricts hepatic uptake of low-density lipoprotein (LDL) cholesterol by promoting the degradation of LDL receptors (LDLR). PCSK9 and LDLR are also expressed in insulin-producing pancreatic islet β cells, possibly affecting the function of these cells. Here we show that, compared to control mice, PCSK9-null male mice over 4 months of age carried more LDLR and less insulin in their pancreas; they were hypoinsulinemic, hyperglycemic and glucose-intolerant; their islets exhibited signs of malformation, apoptosis and inflammation. Collectively, these observations suggest that PCSK9 may be necessary for the normal function of pancreatic islets. Abbreviations: IB, immunoblotting, IP, immunoprecipitation, LDL, low-density lipoprotein, LDL-C, LDL-cholesterol, LDLR, LDL receptor, OGTT, oral glucose tolerance test, qRT-PCR, quantitative reverse transcriptase-polymerase chain reaction, PCSK9, proprotein convertase subtilisin/kexin type 9, sqIB, semi-quantitative immunoblotting, TBP, TATA-box binding protein a Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada b Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada c Division of Endocrinology and Metabolism, The Ottawa Hospital, Ottawa, Ontario, Canada d Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, Quebec, Canada Corresponding author. Present address: Ottawa Hospital Research Institute, 725 Parkdale Avenue, Ottawa, Ontario, Canada K1Y 4E9. Fax: +1 613 761 4355.
PII: S0014-5793(09)01064-3 doi:10.1016/j.febslet.2009.12.018 © 2009 Federation of European Biochemical Societies | |
|
|